Log in

Akebia Therapeutics Stock Price, News & Analysis (NASDAQ:AKBA)

$4.16
-0.14 (-3.26 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$4.12
Now: $4.16
$4.40
50-Day Range
$3.77
MA: $4.32
$5.21
52-Week Range
$3.50
Now: $4.16
$10.45
Volume448,153 shs
Average Volume783,535 shs
Market Capitalization$494.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$207.74 million
Book Value$5.44 per share

Profitability

Net Income$-143,590,000.00

Miscellaneous

Employees324
Market Cap$494.46 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.


Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.05. The biopharmaceutical company earned $100.80 million during the quarter, compared to the consensus estimate of $88.35 million. Akebia Therapeutics had a negative return on equity of 36.92% and a negative net margin of 75.64%. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

4 Wall Street analysts have issued twelve-month price objectives for Akebia Therapeutics' shares. Their forecasts range from $9.00 to $17.00. On average, they anticipate Akebia Therapeutics' stock price to reach $13.50 in the next year. This suggests a possible upside of 224.5% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

What is the consensus analysts' recommendation for Akebia Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/15/2019)
  • 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019)

Has Akebia Therapeutics been receiving favorable news coverage?

Media coverage about AKBA stock has trended very negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akebia Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Akebia Therapeutics.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), TherapeuticsMD (TXMD), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), Energy Transfer LP Unit (ET), FireEye (FEYE), Flexion Therapeutics (FLXN), NVIDIA (NVDA) and Bank of America (BAC).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
  • Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $4.16.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $494.46 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is http://www.akebia.com/.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]


MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  583
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel